Name (Synonyms) | Correlation | |
---|---|---|
drug360 | Hydroxychloroquine Wiki | 0.09 |
drug616 | Placebo Wiki | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.10 |
D003141 | Communicable Diseases NIH | 0.08 |
D018352 | Coronavirus Infections NIH | 0.08 |
D007239 | Infection NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
There are 2 clinical trials
The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization and the rate of morbidity and mortality in patients with severe COVID-19 compared to placebo.
Description: The ViVi or Vienna Vaccine Safety Initiative Disease Severity Score ranges from 0 to 22 with the disease severity indicated by increasing score. It is used to score disease severity and risk in patients with influenza-like illness and/or other forms of acute respiratory infections (e.g. RSV, adenovirus metapneumovirus, rhinovirus and other respiratory viral pathogens), including in infants and children. The Investigator will ask yes/no questions to the patient, and the mobile application will automatically calculate the score.
Measure: Change in Vienna Vaccine Safety Initiative (ViVI) Disease Severity Score Time: Up to Day 28The main purpose of this study is to evaluate the activity, safety and reduction in mortality of two regimens of low dose selinexor (KPT-330) in patients with moderate or severe COVID-19.